Literature DB >> 17100757

The influence of previous exposure to environmental mycobacteria on the interferon-gamma response to bacille Calmette-Guérin vaccination in southern England and northern Malawi.

R E Weir1, G F Black, B Nazareth, S Floyd, S Stenson, C Stanley, K Branson, L Sichali, S D Chaguluka, L Donovan, A C Crampin, P E M Fine, H M Dockrell.   

Abstract

We report a large study of the effect of BCG vaccination on the in vitro 6-day whole blood interferon-gamma (IFN-gamma) response to antigens from eight species of mycobacteria among schoolchildren in south-eastern England, where bacille Calmette-Guérin (BCG) vaccination is highly protective against pulmonary tuberculosis, and among young adults in northern Malawi, where BCG vaccination is not protective. In the UK children, BCG induced an appreciable increase in IFN-gamma response to antigens from most species of mycobacteria. The degree of change was linked to the relatedness of the species to Mycobacterium bovis BCG, and provides further evidence of the cross-reactivity of mycobacterial species in priming of the immune system. IFN-gamma responses to purified protein derivatives (PPDs) from M. tuberculosis and environmental mycobacteria were more prevalent in the Malawian than the UK group prior to vaccination; BCG vaccination increased the prevalence of responses to these PPDs in the UK group to a level similar to that in Malawi. There was no evidence that the vaccine-induced change in IFN-gamma response was dependent upon the magnitude of the initial response of the individual to environmental mycobacteria in the United Kingdom or in Malawi. These observations should assist the development and interpretation of human clinical trials of new vaccines against M. tuberculosis in areas of both low and high exposure to environmental mycobacteria.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17100757      PMCID: PMC1810413          DOI: 10.1111/j.1365-2249.2006.03222.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

1.  Patterns and implications of naturally acquired immune responses to environmental and tuberculous mycobacterial antigens in northern Malawi.

Authors:  G F Black; H M Dockrell; A C Crampin; S Floyd; R E Weir; L Bliss; L Sichali; L Mwaungulu; H Kanyongoloka; B Ngwira; D K Warndorff; P E Fine
Journal:  J Infect Dis       Date:  2001-07-10       Impact factor: 5.226

2.  Influence of sensitisation to environmental mycobacteria on subsequent vaccination against bovine tuberculosis.

Authors:  Bryce M Buddle; Barry J Wards; Frank E Aldwell; Desmond M Collins; Geoffrey W de Lisle
Journal:  Vaccine       Date:  2002-01-15       Impact factor: 3.641

3.  Immunogenicity of various mycobacteria and the corresponding levels of cross-protection developed between species.

Authors:  F M Collins
Journal:  Infect Immun       Date:  1971-12       Impact factor: 3.441

4.  Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.

Authors:  Lise Brandt; Joana Feino Cunha; Anja Weinreich Olsen; Ben Chilima; Penny Hirsch; Rui Appelberg; Peter Andersen
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

5.  Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.

Authors:  C E Palmer; M W Long
Journal:  Am Rev Respir Dis       Date:  1966-10

6.  BCG-induced increase in interferon-gamma response to mycobacterial antigens and efficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies.

Authors:  Gillian F Black; Rosemary E Weir; Sian Floyd; Lyn Bliss; David K Warndorff; Amelia C Crampin; Bagrey Ngwira; Lifted Sichali; Bernadette Nazareth; Jenefer M Blackwell; Keith Branson; Steven D Chaguluka; Linda Donovan; Elizabeth Jarman; Elizabeth King; Paul E M Fine; Hazel M Dockrell
Journal:  Lancet       Date:  2002-04-20       Impact factor: 79.321

7.  BCG and vole bacillus vaccines in the prevention of tuberculosis in adolescence and early adult life.

Authors:  P D Hart; I Sutherland
Journal:  Br Med J       Date:  1977-07-30

8.  Phylogeny of rapidly growing members of the genus Mycobacterium.

Authors:  C Pitulle; M Dorsch; J Kazda; J Wolters; E Stackebrandt
Journal:  Int J Syst Bacteriol       Date:  1992-07

9.  Exposure to Mycobacterium avium primes the immune system of calves for vaccination with Mycobacterium bovis BCG.

Authors:  C J Howard; L S Kwong; B Villarreal-Ramos; P Sopp; J C Hope
Journal:  Clin Exp Immunol       Date:  2002-11       Impact factor: 4.330

10.  Interferon-gamma and skin test responses of schoolchildren in southeast England to purified protein derivatives from Mycobacterium tuberculosis and other species of mycobacteria.

Authors:  R E Weir; P E M Fine; B Nazareth; S Floyd; G F Black; E King; C Stanley; L Bliss; K Branson; H M Dockrell
Journal:  Clin Exp Immunol       Date:  2003-11       Impact factor: 4.330

View more
  32 in total

1.  Potentially pathogenic nontuberculous mycobacteria found in aquatic systems. Analysis from a reclaimed water and water distribution system in Mexico City.

Authors:  A I Castillo-Rodal; M Mazari-Hiriart; L T Lloret-Sánchez; B Sachman-Ruiz; P Vinuesa; Y López-Vidal
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-07-30       Impact factor: 3.267

Review 2.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

3.  An Expanding Role for Environmental Microbes in Shaping the Immune Response to Infection with Mycobacterium tuberculosis.

Authors:  David M Lewinsohn
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

Review 4.  Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis.

Authors:  Javeed A Shah; Cecilia S Lindestam Arlehamn; David J Horne; Alessandro Sette; Thomas R Hawn
Journal:  J Infect Dis       Date:  2019-08-30       Impact factor: 5.226

5.  What has Karonga taught us? Tuberculosis studied over three decades.

Authors:  A C Crampin; J R Glynn; P E M Fine
Journal:  Int J Tuberc Lung Dis       Date:  2009-02       Impact factor: 2.373

6.  A longitudinal study of BCG vaccination in early childhood: the development of innate and adaptive immune responses.

Authors:  Yenny Djuardi; Erliyani Sartono; Heri Wibowo; Taniawati Supali; Maria Yazdanbakhsh
Journal:  PLoS One       Date:  2010-11-19       Impact factor: 3.240

7.  Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

Authors:  Tony Hawkridge; Thomas J Scriba; Sebastian Gelderbloem; Erica Smit; Michele Tameris; Sizulu Moyo; Trudie Lang; Ashley Veldsman; Mark Hatherill; Linda van der Merwe; Helen A Fletcher; Hassan Mahomed; Adrian V S Hill; Willem A Hanekom; Gregory D Hussey; Helen McShane
Journal:  J Infect Dis       Date:  2008-08-15       Impact factor: 5.226

8.  Population differences in immune responses to Bacille Calmette-Guérin vaccination in infancy.

Authors:  Maeve K Lalor; Anne Ben-Smith; Patricia Gorak-Stolinska; Rosemary E Weir; Sian Floyd; Rose Blitz; Hazzie Mvula; Melanie J Newport; Keith Branson; Nuala McGrath; Amelia C Crampin; Paul E M Fine; Hazel M Dockrell
Journal:  J Infect Dis       Date:  2009-03-15       Impact factor: 5.226

9.  BCG and New Preventive Tuberculosis Vaccines: Implications for Healthcare Workers.

Authors:  Mark Hatherill; Thomas J Scriba; Zarir F Udwadia; Jai B Mullerpattan; Anthony Hawkridge; Hassan Mahomed; Christopher Dye
Journal:  Clin Infect Dis       Date:  2016-05-15       Impact factor: 9.079

Review 10.  100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19.

Authors:  Niyati Lobo; Nathan A Brooks; Alexandre R Zlotta; Jeffrey D Cirillo; Stephen Boorjian; Peter C Black; Joshua J Meeks; Trinity J Bivalacqua; Paolo Gontero; Gary D Steinberg; David McConkey; Marko Babjuk; J Alfred Witjes; Ashish M Kamat
Journal:  Nat Rev Urol       Date:  2021-06-15       Impact factor: 14.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.